ZW-49 Uses, Dosage, Side Effects and more

According to Zymeworks, "ZW49 is a bispecific anti-HER2 ADC that is based on the same antibody framework as ZW25 but armed with a cytotoxic payload." It is being investigated for several indications characterized by HER2 expression including breast and gastric cancers that have progressed or are refractory to existing HER2-targeted therapies, and other HER2 expressing solid tumors.

Attribute	Details
Trade Name	ZW-49
Generic	ZW-49
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	January 7, 2025 at 1:49 am

Innovators Monograph